ASCLS eNewsBytes

• Influenza Vaccination in Juvenile Idiopathic Athritis Linked to COVID-19 Pandemic, Caregiver Demographics February 2, 2026
  Influenza vaccination rates for children with juvenile idiopathic arthritis in Central and Eastern Europe rose notably during the COVID-19 pandemic, linked to caregivers' education, employment status and recommendations from physicians.
• The Cellular Marathon: How Muscle Stem Cells Shift Gears as Bodies Age February 2, 2026
  New research indicates that as muscle stem cells age, they transition from a quick glycolytic metabolism to a slower oxidative phosphorylation, which reduces their regenerative ability. This metabolic change may be reversible, presenting potential therapeutic avenues for addressing age-related muscle loss and sarcopenia in older adults.
• FDA Approves Updated Prescribing Information for Inhaled Insulin Powder, Including New Starting Dose Guidance February 2, 2026
  The FDA has approved an update to the prescribing information for inhaled human insulin powder, adjusting the recommended starting mealtime dosing for adults moving from subcutaneous insulin regimens, such as multiple daily injections or insulin pump therapy.
• Oral Bacterium May Promote Breast Cancer Development and Spread February 2, 2026
  Researchers at Johns Hopkins Kimmel Cancer Center discovered that an oral bacterium linked to periodontal disease can trigger breast cancer development, enhance tumor growth and facilitate metastasis by causing DNA damage and modifying cancer cell behavior.
• FDA Approval of Perioperative Enfortumab Vedotin Plus Pembrolizumab Redefines Cisplatin-Ineligible MIBC Care February 2, 2026
  The FDA's approval of enfortumab vedotin-ejfv alongside pembrolizumab, or pembrolizumab and berahyaluronidase alfa-pmph, for use in perioperative treatment of cisplatin-ineligible muscle-invasive bladder cancer signifies a significant advancement in managing this condition.